glp-1 cardiovascular outcomes 2025 news ISPOR 2025: Exploring reasons for discontinuation SGLTi and GLP-1 in HF

GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D 2

Free domestic shipping on every order

Both medications may improve cardiovascular health by reducing blood pressure, cholesterol, and inflammation

Prioritize protein at every meal

[DOI] [PMC free article] [PubMed] [Google Scholar] 148.Di Francesco V., Barazzoni R., Bissoli L., Fantin F., Rizzotti P., Residori L., Antonioli A., Graziani M.S., Zanetti M., Bosello O., et al

The above meta-analyses comprised all clinical trials we could retrieve with our search 52,183,184,185,186,189,191,196,197,198,199,200